MELBOURNE, AUSTRALIA--(Marketwire - May 13, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced a publication in the Proceedings of the National Academy of Sciences (PNAS) journal,(1) describing a completely new class of amyloid inhibiting drugs.
